about
Standardization of cytokine flow cytometry assaysImmune activation alters cellular and humoral responses to yellow fever 17D vaccineLong-term follow-up of study participants from prophylactic HIV vaccine clinical trials in AfricaIn vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteersSafety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in AfricaCTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya: use of multiple peptide sets increases the detectable breadth of the CTL response.Circulating and unique recombinant forms of HIV type 1 containing subsubtype A2.Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessmentEvaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials.Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccineCryopreservation-related loss of antigen-specific IFNγ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy.A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adultsPhase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidateEquivalence of ELISpot assays demonstrated between major HIV network laboratoriesQuality monitoring of HIV-1-infected and uninfected peripheral blood mononuclear cell samples in a resource-limited setting.Intra- and inter-clade cross-reactivity by HIV-1 Gag specific T-cells reveals exclusive and commonly targeted regions: implications for current vaccine trialsThe External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assayEstablishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials.Comprehensive screening for human immunodeficiency virus type 1 subtype-specific CD8 cytotoxic T lymphocytes and definition of degenerate epitopes restricted by HLA-A0207 and -C(W)0304 allelesA phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses.Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteersBroad HIV epitope specificity and viral inhibition induced by multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adultsA Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients.Lost in translation: implications of HIV-1 codon usage for immune escape and drug resistance.Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.A high viral burden predicts the loss of CD8 T-cell responses specific for subdominant gag epitopes during chronic human immunodeficiency virus infectionMagnitude, breadth, and functional profile of T-cell responses during human immunodeficiency virus primary infection with B and BF viral variants.Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development.Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunityBroad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or PolyphosphazeneConcordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents.
P50
Q24811983-6586FB36-05EA-4745-B668-EA06C1A68AABQ28388716-9DCB9DE8-4FA5-4882-8607-1D7853A5DE2CQ28654629-EFBA4C48-2BCB-4AEC-8733-9F81C005B1F1Q28744555-357FA724-0D6A-43B2-BBE5-7F90E80B50E9Q28749224-9257DE5B-13E2-421A-9F7D-11B9B3A94159Q30353953-1A0489D4-0AC4-4B3F-86BE-3E55B2552810Q30355419-14FECA38-E209-44BD-BF74-C8E08B6E8BC6Q30977303-4F58CD5B-FD2E-460E-A1DC-D44CCF5E0D67Q31031447-92BBD579-2579-4908-9DA2-3EBD5EFDC77AQ33310152-AA60550B-D647-44A6-BCEA-3199E1FF5048Q33470284-2867EE94-27AC-460B-9866-398F25497222Q33527383-2E181638-640A-4276-BE83-C67942C1B059Q33551527-D382FEE7-E72B-4EAA-AE74-85C904CC2B9AQ33611719-95AE261E-4371-427E-9747-484A6F6302A4Q33747721-7479EECE-79FF-4F85-9375-677600D07E67Q33749950-040E4068-006A-4227-BD4C-C279DB29D569Q33778327-589D51C5-845A-4E80-AA35-9680B133DB79Q33909178-F150703C-5818-4DF3-93C9-0D078FC633BCQ34055991-A295D3FF-73AC-4B3E-BBD0-FF8C72EF0AB2Q34066932-A4668C32-1896-4BD7-95D8-3E98432AD0B1Q34125277-9A5AB2C5-F5AA-49CF-9D2B-560E953B036AQ34339044-BD2166CD-494C-4317-A746-CE9B94606DCBQ34369139-8A8396D1-24C1-41BC-95F7-500C0FFE9A31Q34438489-04C89BEE-98EB-4D48-982E-EAE04739C89BQ34535266-E0CA8188-A293-486A-BB8C-ED5C327FB5EEQ34589611-53AC3CCB-DC8D-4BE9-AEE7-8571EA3CC8ECQ35114907-37C7B11B-1C51-41A0-A005-146E330663B2Q35593139-FBAD2881-7658-44E2-ADEF-1CCCC868AD45Q35739841-2A36537B-18E9-477A-8D12-9AD705FDD4B4Q35784745-35AC225E-C5FD-4712-B29A-10AA4F9731DBQ35787588-D780B35C-468F-42D5-83D0-D396C3647B9EQ35883032-A6148B0E-E4A2-47D6-AF2E-95A53E462376Q36315080-A5A2B38E-4469-4296-93C3-3BECC64B70B9Q36484094-DBD1727C-2798-43A1-A6AD-D295D230F702Q36600351-B9B7C095-AC88-4973-AE40-F8C61540E9D6Q36668517-9F19904E-7307-450A-849B-911D7450F691Q36679394-2116E601-CD7D-4FFB-B9C2-D277A06B4700Q36692389-F38843D0-51B5-49C8-A895-102D63D77170Q36931790-AA3E43B5-1EBD-46E2-BC44-8E97BEBDFFB4Q37099271-223B5C3C-40F7-4860-9994-6F13FE90169E
P50
description
Forscher
@de
chercheur
@fr
hulumtuese
@sq
investigador
@es
researcher
@en
ricercatore
@it
研究者
@zh
name
Josephine H Cox
@ast
Josephine H Cox
@en
Josephine H Cox
@es
Josephine H Cox
@nl
type
label
Josephine H Cox
@ast
Josephine H Cox
@en
Josephine H Cox
@es
Josephine H Cox
@nl
prefLabel
Josephine H Cox
@ast
Josephine H Cox
@en
Josephine H Cox
@es
Josephine H Cox
@nl
P108
P108
P1153
7404023564
P21
P31
P496
0000-0003-1301-7373